Compounds > 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone
Page last updated: 2024-11-04

2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2876
CHEMBL ID92659
SCHEMBL ID2599202
MeSH IDM0414230

Synonyms (31)

Synonym
CHEMBL92659 ,
NCI60_025617
nsc-672121
2-hydroxyethylthio-3-methylnaphthoquinone
nsc672121
SMP2_000122
2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone
2-(2-hydroxy-ethylsulfanyl)-3-methyl-[1,4]naphthoquinone
2-(2-hydroxyethylthio)-3-methylnaphthalene-1,4-dione
bdbm50118676
BRD-K55292075-001-01-0
2-(2-hydroxyethylsulfanyl)-3-methylnaphthalene-1,4-dione
2-[(2-hydroxyethyl)thio]-3-methyl-1,4-naphthoquinone
59147-84-1
AKOS016011513
2-((2-hydroxyethyl)thio)-3-methylnaphthalene-1,4-dione
AM807678
SCHEMBL2599202
DTXSID50274390
2-[(2-hydroxyethyl)sulfanyl]-3-methylnaphthalene-1,4-dione
2-(2-hydroxyethyl)thio-3-methyl-1,4-naphthoquinone
2-[(2-hydroxyethyl)sulfanyl]-3-methyl-1,4-dihydronaphthalene-1,4-dione
AS-69105
2-[(2-hydroxyethyl)thio]-3-methyl-1,4-naphthalenedione
FT-0712526
cpd 5 (pharmaceutical)
nsc 672121
I10534
CS-0061155
BCP21745
AC-37078
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
M-phase inducer phosphatase 1Homo sapiens (human)IC50 (µMol)4.53000.02204.20249.4000AID1517763; AID362942
M-phase inducer phosphatase 2Homo sapiens (human)IC50 (µMol)17.26500.10002.31039.5100AID1517765; AID362943
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein S100-A4Homo sapiens (human)EC50 (µMol)62.00003.80005.70007.6000AID1618872
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
epithelial to mesenchymal transitionProtein S100-A4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein S100-A4Homo sapiens (human)
positive chemotaxisProtein S100-A4Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityM-phase inducer phosphatase 1Homo sapiens (human)
G1/S transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cell population proliferationM-phase inducer phosphatase 1Homo sapiens (human)
response to radiationM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cellular response to UVM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of DNA replicationM-phase inducer phosphatase 1Homo sapiens (human)
cell divisionM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
oocyte maturationM-phase inducer phosphatase 2Homo sapiens (human)
protein phosphorylationM-phase inducer phosphatase 2Homo sapiens (human)
female meiosis IM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cell population proliferationM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cytokinesisM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
cell divisionM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
RNA bindingProtein S100-A4Homo sapiens (human)
actin bindingProtein S100-A4Homo sapiens (human)
protein bindingProtein S100-A4Homo sapiens (human)
chemoattractant activityProtein S100-A4Homo sapiens (human)
identical protein bindingProtein S100-A4Homo sapiens (human)
transition metal ion bindingProtein S100-A4Homo sapiens (human)
RAGE receptor bindingProtein S100-A4Homo sapiens (human)
calcium-dependent protein bindingProtein S100-A4Homo sapiens (human)
calcium ion bindingProtein S100-A4Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein-folding chaperone bindingM-phase inducer phosphatase 1Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein bindingM-phase inducer phosphatase 2Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
extracellular spaceProtein S100-A4Homo sapiens (human)
extracellular regionProtein S100-A4Homo sapiens (human)
extracellular spaceProtein S100-A4Homo sapiens (human)
nucleusProtein S100-A4Homo sapiens (human)
nucleoplasmProtein S100-A4Homo sapiens (human)
cytosolProtein S100-A4Homo sapiens (human)
perinuclear region of cytoplasmProtein S100-A4Homo sapiens (human)
collagen-containing extracellular matrixProtein S100-A4Homo sapiens (human)
extracellular exosomeProtein S100-A4Homo sapiens (human)
perinuclear region of cytoplasmProtein S100-A4Homo sapiens (human)
nucleusProtein S100-A4Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 1Homo sapiens (human)
cytosolM-phase inducer phosphatase 1Homo sapiens (human)
nucleusM-phase inducer phosphatase 1Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 1Homo sapiens (human)
spindle poleM-phase inducer phosphatase 2Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 2Homo sapiens (human)
centrosomeM-phase inducer phosphatase 2Homo sapiens (human)
cytosolM-phase inducer phosphatase 2Homo sapiens (human)
nucleusM-phase inducer phosphatase 2Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID763579Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Anticancer activity and SAR studies of substituted 1,4-naphthoquinones.
AID106326Concentration required for 50% inhibition of growth in human uterine sarcoma (MES-SA) cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID210317Concentration required for 50% inhibition of growth in human nasopharyngeal carcinoma (TW-039) cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID1517787Binding affinity to MKK7 (unknown origin) expressed in HEK293 cells assessed as dissociation constant at <30 uM by kinomescan method2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517769Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517776Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID88736Concentration required for 50% inhibition of growth in human liver hepatoblastoma (Hep G2) cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID1517768Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517774Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID106870Concentration required for 50% inhibition of growth in human stomach adenocarcinoma (MKN45) cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID218267Concentration required for 50% inhibition of growth in normal human lung fibroblast (WI-38 cell line) cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID1517770Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID763580Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Anticancer activity and SAR studies of substituted 1,4-naphthoquinones.
AID1517772Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID362942Inhibition of Cdc25A (336-523) expressed in Escherichia coli2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening.
AID56738Concentration required for 50% inhibition of growth in normal human embryonic skin fibroblast (Detroit551c) cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID201693Concentration required for 50% inhibition of growth in human colon adenocarcinoma (SW-480) cell line.2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID1517773Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID763573Binding affinity to STAT3 SH2 domain (unknown origin) using 5-FAM-SpYLPQTV as probe assessed as inhibition of protein dimerization at 500 uM after 60 mins by fluorescence polarization assay relative to control2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Anticancer activity and SAR studies of substituted 1,4-naphthoquinones.
AID1517771Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID763578Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Anticancer activity and SAR studies of substituted 1,4-naphthoquinones.
AID9025Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID1517765Inhibition of recombinant Cdc25B (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID106336Concentration required for 50% inhibition of growth in human multidrug resistance uterine sarcoma (MES-SA/Dx5 ) cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID1517767Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517763Inhibition of recombinant Cdc25A (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID103557Concentration required for 50% inhibition of growth in mammary gland breast adenocarcinoma (MCF-7) cell line was determined2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID1517775Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517790Inhibition of recombinant HNE (unknown origin) at <50 uM using N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin, as a substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID86240Dose required for 50% inhibition of growth of Hep3B cells2002Bioorganic & medicinal chemistry letters, Oct-07, Volume: 12, Issue:19
Synthesis and anticancer evaluation of vitamin K(3) analogues.
AID362943Inhibition of Cdc25B (378-566) expressed in Escherichia coli2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (83.33)29.6817
2010's3 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.34 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2,3-dimethoxy-1,4-naphthoquinone
2,3-dimethoxynaphthalene-1,4-dione : A naphthoquinone that is 1,4-naphthoquinone bearing two methoxy substituents at positions 2 and 3. Redox-cycling agent that induces intracellular superoxide anion formation and, depending on the concentration, induces cell proliferation, apoptosis or necrosis. Used to study the role of ROS in cell toxicity, apoptosis, and necrosis.		2.21101,4-naphthoquinones
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
juglone
juglone: structure. juglone : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogen at position 5 has been replaced by a hydroxy group. A plant-derived 1,4-naphthoquinone with confirmed antibacterial and antitumor activities.		2.0810hydroxy-1,4-naphthoquinonegeroprotector;
herbicide;
reactive oxygen species generator
lapachol
lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.		2.2110
vitamin k 3
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.		2.76301,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
n-formylmethionylphenylalanine
[no description available]		2.0610peptide
pd 98059
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.		2.0110aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		2.4120amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
1,4-naphthoquinone
naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties.		2.08101,4-naphthoquinones
plumbagin
plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.		2.5320hydroxy-1,4-naphthoquinone;
phenols		anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite
2-methoxy-1,4-naphthoquinone
2-methoxy-1,4-naphthoquinone: isolated from Swertia calycina; structure in first source. 2-methoxy-1,4-naphthoquinone : A naphthoquinone that is naphthalene-1,4-dione substituted by a methoxy group at position 2. It has been isolated from the roots of Rubia yunnanensis.		2.21101,4-naphthoquinones;
enol ether		antimicrobial agent;
metabolite;
plant metabolite
buparvaquone
buparvaquone: used in therapy of theileriasis; structure given in first source		2.2110
nsc 95397
[no description available]		2.49201,4-naphthoquinones
shikonin
shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities		2.2110hydroxy-1,4-naphthoquinone
2-[[5-(3-chlorophenyl)-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]-1-(3,4-dihydroxyphenyl)ethanone
[no description available]		2.0410aromatic ketone
u 0126
U 0126: protein kinase kinase inhibitor; structure in first source		2.0310aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
vitamin k semiquinone radical
vitamin K semiquinone radical: found in active preparations of vitamin K-dependent carboxylase. vitamin K : Any member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.		4.03140
leukotriene b4
Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.		2.0610dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
su 11248
[no description available]		2.2110monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.0610
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.4120
ConditionIndicatedRelationship StrengthStudiesTrials
Proliferative Vitreoretinopathy
[description not available]		02.0110
Vitreoretinopathy, Proliferative
Vitreoretinal membrane shrinkage or contraction secondary to the proliferation of primarily retinal pigment epithelial cells and glial cells, particularly fibrous astrocytes, followed by membrane formation. The formation of fibrillar collagen and cellular proliferation appear to be the basis for the contractile properties of the epiretinal and vitreous membranes.		02.0110
Hepatocellular Carcinoma
[description not available]		02.9440
Cancer of Liver
[description not available]		02.9340
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.9440
Liver Neoplasms
Tumors or cancer of the LIVER.		02.9340
Experimental Hepatoma
[description not available]		02.0210
Cancer of Kidney
[description not available]		02.0210
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.0210
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Benign Neoplasms
[description not available]		0210
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		0210